C. Rémuzat

Puig (France) — France

Economics, Econometrics and Finance · Social Sciences

16h-index1.2kcitations154works1.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmaceutical Economics and Policy(106), Health Systems, Economic Evaluations, Quality of Life(97), Biosimilars and Bioanalytical Methods(28), Biomedical Ethics and Regulation(19), Pharmaceutical studies and practices(17)

Publications154 total

HTA296 Scoping the Future: Using NICE Scopes to Inform PICO Prediction for EU Joint Clinical Assessment
Value in Health·2025
HTA18 Acceptance of Artificial Intelligence in Evidence and Dossier Development by Global HTA Agencies
Value in Health·2025
HTA240 National Implementation of the EU HTA Regulation: Progress and Strategic Developments Across Member States
Value in Health·2025
HTA151 From French Early Access to Regular Reimbursement: How Do Prices Shift Post-HTA?
Value in Health·2025
HTA68 Strategic Implications of EU HTAR (JCA and JSC) for Global Biopharma and Biotechs: Navigating Evolving Paradigms in Market Access
Value in Health·2025Open Access
PT24 From French Early Access to Reimbursement: A Comparison of Early Access Prices and List Prices
Value in Health·2024Open Access
HTA345 How Are National HTA Bodies Preparing for the Implementation of the EU HTA Regulation?
Value in Health·2024· 1 citedOpen Access
HPR103 Recent Developments in European Voluntary Cross-Border Collaborations in Joint HTA, Drug Pricing, Procurement, and Readiness for EU HTA Implementation
Value in Health·2024Open Access
Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape
Heart Failure Reviews·2024· 13 citedOpen Access
HPR218 Recent Advances in Voluntary European Cross-Border Collaborations in Joint HTA and Drug Pricing/Procurement
Value in Health·2023Open Access
HTA184 Review of HTA Evaluation for Gene Therapies and Their Future Implications in Europe
Value in Health·2023
HTA279 Retrospective Analysis of the French Early Access Experience Following the 2021 Reform
Value in Health·2023
HTA353 Analysis of the Impact of Early Access Decisions on Pricing and Reimbursement Decisions in France
Value in Health·2023Open Access
HTA88 Reimbursement of CAR-T Cell Therapies in Europe: Key Challenges from Precedents and Lessons for Future
Value in Health·2023Open Access
PIN138 National and European Union-LEVEL Recommendations to Accelerate Vaccine Timely Access
Value in Health·2020
PIN140 Drivers and Barriers to Vaccines Timely Access to Population in Europe: Perspectives from Experts Knowlegable of the Decision-Making Process
Value in Health·2020
PIN36 Comparison of Vaccine Market Access Pathways in European and Asian Countries
Value in Health Regional Issues·2020
PNS26 Real-World Evidence in Regulatory Decision-Making: Parallel between FDA in the US and Pmda in JAPAN
Value in Health Regional Issues·2020
PBI7 Comparison of Biosimilar Policies between Key Countries in ASIA, EU and USA
Value in Health Regional Issues·2020Open Access
PBI5 Future Trends on the Biosimilar Uptake in China, JAPAN, the US, the EU4 and the UK
Value in Health Regional Issues·2020Open Access
page 1 of 8Next →

Frequent Co-authors

Mondher Toumi(47), Samuel Aballéa(9), A. Kornfeld(8), Pascal Auquier(6), D. Urbinati(6), A.L. Vataire(6), A. Millier(5), Bruno Falissard(5), C. Chouaïd(5), L. Cetinsoy(5), Olfa Mzoughi(4), Emna El Hammi(4), Dan Ionescu(3), Guerric Radière(3), W Belgaied(3), C Mendoza(3), C. François(3), F Tavella(3), Isabelle Borget(3), D Korchagina(3)